Antonini A, Barone P, Bonuccelli U et al. ICARUS study:prevalence and clinical features of impulse control disorders in Parkinson’s disease.
J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):317-324.
Epis OM, Casu C, Belloli L et al. Pixel or Paper?Validation of a Mobile Technology for Collecting Patient-Reported Outcomes in Rheumatoid Arthritis.
JMIR Res Protoc. 2016 Nov 16;5(4):e219.
Frisinghelli A, Cesana F, Clavario P et al. Italian cardiologists and tobacco smoking.A survey on the prevalence and knowledge of smoking and strategies for smoking cessation in a cohort of Italian cardiologists.
G Ital Cardiol 2015;16: 426-432.
Monteleone G, Neurath MF, Ardizzone S et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease.
N Engl J Med. 2015 Mar 19;372(12):1104-13.
Certan D, Righini V, Oliva M et al.
Bioavailability of l-thyroxine and its metabolites after topical treatment with an emulsion containing 0.1% micronised l-thyroxine.
G Ital Dermatol Venereol. 2013 Jun;148(3):287-92.
Zorzi F, Calabrese E, Monteleone I, et al. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease.
Aliment Pharmacol Ther. 2012 Nov;36(9):850-7.
Monteleone G, Fantini MC, Onali S et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn’s disease.
Mol Ther. 2012 Apr;20(4):870-61st in man mongersen.
Zaim M, Piselli L, Fioravanti P et al. Efficacy and tolerability of a prolonged release ferrous sulphate formulation in iron deficiency anaemia: a non-inferiority controlled trial.
Eur J Nutr. 2012 Mar;51(2):221-9.
Naber KG, Schito G, Botto et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.
Eur Urol. 2008 Nov;54(5):1164-75.